Multiparametric MRI Findings association with Pathological Features and hormonal secretion in Patients with Pituitary Macroadenoma: A Comprehensive Study
Novelty in Biomedicine,
Vol. 13 No. 3 (2025),
27 July 2025
,
Page 144-151
https://doi.org/10.22037/nbm.v13i3.46701
Abstract
Background: Pituitary macroadenoma is a global health concern. Advanced imaging techniques, such as multiparametric magnetic resonance imaging (MRI), have emerged as valuable tools for comprehensively evaluating macroadenomas. This study aimed to evaluate the association between multiparametric MRI findings, pathological features, and type of secretion in patients with pituitary macroadenoma.
Materials and Methods: This cross-sectional study evaluated the association between multiparametric MRI findings and pathological features in patients with pituitary macroadenoma. Patients with pituitary macroadenoma referred to Loghman Hakim Hospital (Tehran-Iran) in 2023 were assessed. Preoperative MRI, including T1W, T2W, DWI, ADC, and CE-MRI, were evaluated for signal intensity, maximum diameter, and tumoral extension. The association between the results of MR imaging and the pathologic findings of the resected macroadenoma was assessed.
Results: Forty-five patients were assessed. The mean age was 48.22 ± 14.58 years, and 55.6% of the patients were male. Most patients (48.9%) had isointense lesion in T1W, and most lesions (57.8%) had heterogeneous signals in T2W. Apparent diffusion coefficient levels (ADC) had no diagnostic value for predicting pathologic subtypes. The most invasion was to the infrasellar among macro adenomas (P-value: 0.037). Among patients with gonadotroph pathology results, invasion to the third ventricle with heterogeneous signal on T2 was more common (P-values<0.05). The mean tumor volume is higher in the Prolactin (PRL) secreting type compared to other categories (P-value: 0.002).
Conclusion: Multiparametric MRI helps predict the pathological diagnosis of pituitary macroadenoma.
- Adenoma
- Pituitary tumor
- Multiparametric magnetic resonance imaging
- Pathology
- Hormone secretion
- Macroadenoma
- ADC
How to Cite
References
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2004;101(3):613-9.
Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. American family physician. 2013;88(5):319-27.
Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. Journal of neuro-oncology. 2014;117:379-94.
McNeill KA. Epidemiology of brain tumors. Neurologic clinics. 2016;34(4):981-98.
Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. European Journal of Endocrinology. 2015;173(5):655-64.
Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16:545-53.
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK). Clinical endocrinology. 2010;72(3):377-82.
Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. The Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4268-75.
Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocrine pathology. 2017;28:228-43.
Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. 2016;52:333-43.
Casar-Borota O. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. 2016.
Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer. 2015;22(2):169-77.
Wei L, Lin SA, Fan K, Xiao D, Hong J, Wang S. Relationship between pituitary adenoma texture and collagen content revealed by comparative study of MRI and pathology analysis. International journal of clinical and experimental medicine. 2015;8(8):12898-905.
Yiping L, Ji X, Daoying G, Bo Y. Prediction of the consistency of pituitary adenoma: a comparative study on diffusion-weighted imaging and pathological results. Journal of Neuroradiology. 2016;43(3):186-94.
Heck A, Ringstad G, Fougner SL, Casar‐Borota O, Nome T, Ramm‐Pettersen J, Bollerslev J. Intensity of pituitary adenoma on T2‐weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical endocrinology. 2012;77(1):72-8.
Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, et al. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Scientific reports. 2018;8(1):6173.
Smith KA, Leever JD, Chamoun RB. Prediction of consistency of pituitary adenomas by magnetic resonance imaging. Journal of Neurological Surgery Part B: Skull Base. 2015:340-3.
Shih RY, Schroeder JW, Koeller KK. Primary tumors of the pituitary gland: radiologic-pathologic correlation. Radiographics. 2021;41(7):2029-46.
Roelfsema F, Pereira AM, Biermasz NR, Veldhuis JD. Hormone secretion by pituitary adenomas is characterized by increased disorderliness and spikiness but more regular pulsing. The Journal of Clinical Endocrinology & Metabolism. 2014;99(10):3836-44.
Wang Y, Li Y, Li B, Zang L, Chen K, Du J, et al. Correlation analysis of anterior pituitary hormone and tumor size in patients with pituitary adenomas. Zhonghua nei ke za zhi. 2023;62(8):979-86.
- Abstract Viewed: 192 times
- pdf Downloaded: 90 times